B-Side Pharma provides an innovative solution for multiple cancer types through JVB-14; a peptide with a novel mechanism of action which inhibits the Heparanase enzyme. B-Side’s intellectual property, experienced management team and unique mechanism of action puts it in a great position to help solve some of the deadliest cancer indications known today, starting from Triple Negative Breast Cancer (TNBC).